GlassScriptPhysician profile
Neil O Gomez
NPI 1558779942
$675.65
in general payments reported to CMS, 2019-2025
14 companies · $207 in 2025
The $207 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $202 · 2022: $118 · 2023: $122 · 2024: $27.77 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $356.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $121.66 | 2023 | Quillichew Er, Quillivant, Dyanavel Xr |
| Astrazeneca Pharmaceuticals LP | $104.59 | 2021-2022 | |
| Kestra Medical Technology Services, INC. | $101.03 | 2025 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $77.51 | 2024-2025 | Lifevest |
| Novo Nordisk INC | $60.00 | 2021 | |
| Abbvie INC. | $41.31 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $34.66 | 2022 | |
| Boston Scientific Corporation | $28.16 | 2022 | |
| Abiomed | $26.21 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.79 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.49 | 2022 | |
| Lilly USA, LLC | $15.10 | 2021 | |
| Chiesi USA, INC. | $13.49 | 2025 | Kengreal |
| Biohaven Pharmaceuticals, INC. | $11.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Gomez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.